- | Immuneering
Health-Care Venture Capitalists Raised Record Total in 2020
Immuneering Corp., a Cambridge, Mass.-based startup that uses computational technology for drug discovery, completed a $62 million Series B round. Cormorant Asset Management led the financing, which included participation from Surveyor Capital, Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates Inc., funds and accounts managed by BlackRock, Perceptive Advisors and LYFE Capital.
- | Compugen
Using Computational Discovery to Build Better Immunotherapies
Compugen is using a computational discovery platform to identify proteins and pathways that drive immune resistance mechanisms to checkpoint inhibitors. We spoke to Anat Cohen-Dayag, CEO of Compugen, about the company’s discovery platform, its efforts to develop new treatments that address patients who don’t respond to current checkpoint inhibitors, and its clinical pipeline in development.
- | Avadel
What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk
The review received financial support from Avadel Pharmaceuticals, which recently filed a new drug application with the US Food & Drug Administration (FDA) for a once-nightly formulation of sodium oxybate. Sodium oxybate is currently available with twice-nightly dosing from Jazz Pharmaceuticals under the brand name Xyrem. Jazz recently received FDA approval for narcolepsy drug Xywav (calcium, magnesium, potassium, and sodium oxybates), which has 92% less sodium content than Xyrem.
- | Immuneering
Immuneering secures $62M series B to advance tech-driven pipeline
Immuneering Corp., a bioinformatics specialist that has for years helped big companies like Teva Pharmaceutical Ltd. and Bristol Myers Squibb Co. better understand their own medicines, has landed $62 million in an oversubscribed series B financing that will help it leverage lessons learned in that journey to build out its own pipeline, starting with IMM-1-104, a dual inhibitor of MEK and a related target.
- | Clene Nanomedicine
Clene goes public with gold-based neurology nanotechnology
Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseasesincluding Parkinson’s disease.
- | Immuneering
Immuneering, Terns raise crossover rounds as IPO queue stands to grow again
With crossover investors lining up to participate, biotechs Immuneering and Terns each raised…
- | Aridis Pharmaceuticals
Using Protein Characterization to Support Regulatory Submissions
Before any biologic drug enters into the clinic, it is essential to have a clear understanding of what exactly the biomolecule entails, according to Vu Truong, CEO of Aridis Pharmaceuticals. That includes both structural and physicochemical characteristics.
- | OncoSec
New and Emerging Drug Classes That Will Outlast the Pandemic
OncoSec’s vaccine, CORVax12, being developed in partnership with Providence Cancer Center in Portland, uses a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed in the National Institute of Allergy and Infectious Diseases (NIAID) laboratories similar to the one used in the newly approved Moderna vaccine. It is being created with a proprietary mixture consisting of Interleukin 12s (IL-12’s).
